# An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy

> **NCT01602120** · PHASE2 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 159 (actual)

## Conditions studied

- Geographic Atrophy

## Interventions

- **DRUG:** Lampalizumab

## Key facts

- **NCT ID:** NCT01602120
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05-29
- **Primary completion:** 2017-11-08
- **Final completion:** 2018-02-09
- **Target enrollment:** 159 (ACTUAL)
- **Why stopped:** The study was terminated early by the Sponsor due to lack of efficacy.
- **Last updated:** 2019-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01602120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01602120, "An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01602120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*